1 August 2016
Cambridge, MA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has today announced that its CEO, François Torche, has been selected by PharmaVOICE as one of the top 100 most influential people in the life-sciences industry. François was recognized for his pivotal role in developing and promoting Central Statistical Monitoring (CSM), a ground-breaking concept that is transforming the assessment of data quality in clinical trials.
François was also acknowledged for his personable, energetic and approachable management style, which has earned him deserved respect from the industry and his team at CluePoints, and sets him apart as a truly inspirational leader. Since its launch in 2005, the PharmaVOICE 100 has been celebrating those exceptional professionals in the life-sciences industry who provide inspiration to their peers, colleagues, and companies through their innovative and motivational approaches to addressing the industry’s myriad challenges.
Commenting on the award, François said: “I am immensely honored to have been recognized by PharmaVOICE. This achievement is really a testament to the dedication of the entire CluePoints team, who have shown unwavering commitment to continuously developing and building on the capabilities of our technology, and who share my passion and belief in the benefits CSM can bring to patients, sponsors, CROs, and sites.
“Over recent years, CluePoints has helped to shape the industry’s discussion on quality management and inspired many organizations to re-think their approach to centralized monitoring techniques as they seek to implement risk-based monitoring. This is something I’m extremely proud to have been part of.”
Under François’ leadership, CluePoints has been recognized for several prestigious industry awards, including its recent Clinical & Research Excellence Awards nomination.
For further information on CluePoints’ solutions, please visit www.CluePoints.com
CluePoints is the premier provider of Risk-Based Monitoring and Data Quality Oversight Software. Our products utilize statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and the new ICH (E6) addendum, CluePoints is deployed to support traditional monitoring and data management and can be implemented as the ultimate engine to drive Risk-Based Monitoring. The value of CluePoints lies in its powerful and timely ability to identify anomalous data and site errors allowing optimization of central and on-site monitoring and a significant reduction in overall regulatory submission risk.
Patrick Hughes – Chief Commercial Officer, CluePoints
+44 (0) 7703 532 749